PT  - JOURNAL ARTICLE
AU  - David M. Goldenberg
AU  - Malik Juweid
AU  - Robert M. Dunn
AU  - Robert M. Sharkey
TI  - Cancer Imaging with Radiolabeled Antibodies: New Advances with Technetium-99m-Labeled Monoclonal Antibody Fab’ Fragments, Especially CEA-Scan® and Prospects for Therapy
DP  - 1997 Mar 01
TA  - Journal of Nuclear Medicine Technology
PG  - 18--23
VI  - 25
IP  - 1
4099  - http://tech.snmjournals.org/content/25/1/18.short
4100  - http://tech.snmjournals.org/content/25/1/18.full
SO  - J. Nucl. Med. Technol.1997 Mar 01; 25
AB  - The use of radiolabeled anticancer antibodies to detect cancer sites by external scintigraphy has had a relatively long history. With the advent of monoclonal antibodies (MAbs), which precluded the need for purifying the antibodies by laborious purification steps, there was a surge of interest and efforts to develop these reagents for both imaging and therapy applications (1). Today, many thousands of patients have received different forms and doses of MAbs for various purposes, and four MAb-based products have been licensed for manufacture and sale in the U.S. (2,3). This article describes the most recent MAb product to be approved in the U.S. for colorectal cancer imaging, including discussions of using this agent and its therapeutic counterpart in several cancer types.